Evidence map›Paper›PMID 36566262›Full record

ArticleDrug delivery and translational research2023

Short-chain fatty acid-mediated epigenetic modulation of inflammatory T cells in vitro.

David A McBride, Nicholas C Dorn, Mina Yao, Wade T Johnson, Wei Wang, Nunzio Bottini, Nisarg J Shah

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery and translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Recent advances in the positive role ofFrontiers in immunology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

David A McBride *Department of NanoEngineering, University of California, San Diego, La Jolla, CA, 92093, USA.
Nicholas C Dorn *Department of NanoEngineering, University of California, San Diego, La Jolla, CA, 92093, USA.
Mina YaoDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093, USA.
Wade T JohnsonDepartment of NanoEngineering, University of California, San Diego, La Jolla, CA, 92093, USA.
Wei WangDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093, USA.
Nunzio BottiniDepartment of Medicine, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, 92093, USA.
Nisarg J ShahDepartment of NanoEngineering, University of California, San Diego, La Jolla, CA, 92093, USA. nshah@ucsd.edu.ORCID http://orcid.org/0000-0003-1727-5732
University of California San Diego · US

Funding

Resource-based Center for the study of the joint microenvironment in rheumatology (Overall Application)P30AR073761 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHUNG, CHRISTINE B · 2018 to 2022
$3.9M
Rheumatic Diseases Research Training GrantT32AR064194 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GARY S FIRESTEIN, Monica Guma · 2013 to 2026
$3.8M
Microparticles Modulating Regulatory T cells in Periodontal DiseaseR03DE031009 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHAH, NISARG J. · 2021 to 2022
$286k
Engineered biomaterials modulating inflammatory T cells in rheumatic arthritisF31AR079921 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MCBRIDE, DAVID AMBROSE · 2021 to 2022
$79k
NIAMS NIH HHS F31 AR079921NIAMS NIH HHS P30 AR073761NIAMS NIH HHS T32 AR064194NIDCR NIH HHS R03DE031009
6 · The paper itself

Abstract

Short-chain fatty acids (SCFAs) are major metabolic products of indigestible polysaccharides in the gut and mediate the function of immune cells to facilitate homeostasis. The immunomodulatory effect of SCFAs has been attributed, at least in part, to the epigenetic modulation of immune cells through the inhibition the nucleus-resident enzyme histone deacetylase (HDAC). Among the downstream effects, SCFAs enhance regulatory T cells (T

Indexed as

ButyratesFatty Acids, VolatileChromatinEpigenesis, GeneticT-Lymphocytes, RegulatoryValeratesButyratesChromatinFatty Acids, VolatileValeratesEpigenetic modulationImmunomodulationShort-chain fatty acidsT cells

Identifiers

PMID36566262
PMCPMC10695156
OpenAlexW4312140680

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.